ACIP
COVID-19 Vaccination Recommendations
Next ACIP Meeting
June 22 – 23, 2022: 10:00am – 5:00pm ET
These meetings are virtual. No registration is required to watch the webcasts.
Contact ACIP Secretariat
1600 Clifton Road, N.E., Mailstop H24-8
Atlanta, GA 30329-4027
acip@cdc.gov
email_03Get Email Updates
To receive email updates about this page, enter your email address:
Meeting Recommendations
June 2022
ACIP approved the following recommendations by majority vote at its June 22-23, 2022 meeting:
- ACIP recommends that adults aged ≥65 years preferentially receive one of the following influenza vaccines: quadrivalent high-dose inactivated influenza vaccine (HD-IIV4), quadrivalent recombinant influenza vaccine (RIV4), or quadrivalent adjuvanted inactivated influenza vaccine (aIIV4). If none of these three vaccines is available at an opportunity for vaccine administration, then any other age-appropriate influenza vaccine should be used.
- Affirm the updated MMWR Recommendations and Reports, “Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2022-23 Influenza Season.”
- PCV15 (15-valent pneumococcal conjugate vaccine) may be used as an option to PCV13 (13-valent pneumococcal conjugate vaccine) for children aged <19 years according to currently recommended PCV13 dosing and schedules.
- MMR vaccine (Priorix, GSK) according to currently recommended schedules and off-label uses as an option to prevent measles, mumps, and rubella.
These recommendations have been adopted by the CDC Director and will become official once published in MMWR.
Page last reviewed: June 18, 2022
Content source: National Center for Immunization and Respiratory Diseases